Agilent Companion Diagnostic Gains Expanded FDA Approval in Cervical Cancer
Agilent Companion Diagnostic Gains Expanded FDA Approval in Cervical Cancer PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify cervical cancer patients for treatment with KEYTRUDA® (pembrolizumab) SANTA CLARA, Calif., June 12, 2018 Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its... Read more